DSDaniel Spernat

Daniel Spernat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniel Spernat has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Anne‐Maree Haynes

    Prostate Cancer Group, Cancer Research Programme, Garvan Institute of Medical Research

    1 shared publication
  • Bridget Heijkoop

    Urology Department, The Queen Elizabeth Hospital, The University of Adelaide, Level 7A, 28 Woodville rd, Woodville South, SA, 5011, Australia

    1 shared publication
  • Carlo Yuen

    Department of Urology, St Vincent's Hospital

    1 shared publication
  • Changhong Yu

    Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA

    1 shared publication
  • Christine Su Li Lai

    Department of Breast and Endocrine Surgery, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia

    1 shared publication
  • David Ca Walsh

    University of Adelaide, Queen Elizabeth Hospital, South Australia, Australia

    1 shared publication

Latest Publications

  • Open Access

    Retroperitoneal Paraganglioma often Atypical: Short Case Series and Review of the Literature

    by Kah Heng Alexander Lim, Daniel Spernat, Christine Su Li Lai, David Ca Walsh


  • Open Access

    Effectiveness and safety of inpatient versus extended venous thromboembolism (VTE) prophylaxis with heparin following major pelvic surgery for malignancy: protocol for a systematic review

    by Bridget Heijkoop, Natalie Parker, George Kiroff, Daniel Spernat

    Background: Venous thromboembolism (VTE) is a common postoperative complication associated with significant morbidity and mortality. The use of prophylactic heparin postoperatively reduces this risk, and the use of extended duration prophylaxis is becoming increasingly common. Malignancy and pelvic surgery both independently further increase the risk of postoperative VTE and patients undergoing major pelvic surgery for malignancy are at particularly high risk of VTE. However, the optimum duration of prophylaxis specifically in this population currently remains unclear. Methods: We will conduct a systematic review of literature in accordance with the Cochrane Handbook for Systematic Reviews of Interventions (Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0.,2011) to evaluate current evidence of the effectiveness and safety of inpatient versus extended VTE prophylaxis with heparin (all forms) following major pelvic surgery for malignancy. We will search PubMed, EMBASE, and the Cochrane Library. Regarding safety, Food and Drug Administration (FDA), and Therapeutic Goods Administration (TGA) websites will be searched, including all levels of evidence. Results will be the postoperative timeframe in which a VTE event can be considered to have been provoked by the surgery, and the number of patients needed to treat with both inpatient and extended prophylaxis to prevent a VTE event in this timeframe, comparing these to determine if there is a significant benefit from extended prophylaxis. Discussion: This systematic review will aim to identify the postoperative period in which patients undergoing major pelvic surgery for malignancy are at further increased risk of VTE as a result of their surgery and the optimum duration of heparin VTE prophylaxis with heparin to reduce this risk. Determining this will allow evidence-based recommendations to be made for the optimum duration of heparin VTE prophylaxis post major pelvic surgery for malignancy, leading to improved standards of care that are consistent between different providers and institutions. Systematic review registration: In accordance with guidelines, our systematic review was submitted to PROSPERO for consideration of registration on 16/12/17 and was registered on 12/1/18 with the registration number CRD42018068961, and it was last updated on December 1, 2018.


  • Open Access

    High‐dose rate brachytherapy compared with open radical prostatectomy for the treatment of high‐risk prostate cancer: 10 year biochemical freedom from relapse

    by Richard Savdie, James Symons, Daniel Spernat, Carlo Yuen, Ruth A. Pe Benito, Anne‐Maree Haynes, Jayne Matthews, Krishan K. Rasiah, Raj S. Jagavkar, Changhong Yu, et al.

    Objective To compare long‐term biochemical control of high‐risk prostate cancer in those men receiving high‐dose rate brachytherapy (HDRB) and radical prostatectomy (RP). Patients and methods The 10‐year biochemical freedom from relapse (BFR) was calculated for 243 patients who underwent either RP or combined therapy with HDRB + external beam radiotherapy + androgen deprivation between 1998 and 2000. Inclusion criteria: clinical stage ≥ T2b, or Gleason sum ≥ 8, or PSA level of > 20 ng/mL. Groups were appraised using the Kattan nomogram for surgery to calculate progression‐free probability (PFP). Results For the RP group (153 patients) the median PSA level was 8.1 ng/mL and the median age was 62.2 years. The median 5‐ and 10‐year predicted PFP for RP was 64% and 56 %, respectively. The 5‐ and 10‐year BFR was 65.5% and 55.4%. There was no significant difference between the predicted and the actual PFP for the RP group ( P = 0.525). For HDRB group (90 patients). The median PSA level was 14.2 ng/mL and the median age was 67.6 years. The median 5‐ and 10‐year predicted PFP for HDRB was 46% and 35%, respectively. The 5‐ and 10‐year BFR was 79.6% and 53.6%. There was a significant improvement between the actual and the predicted PFP for the HDRB group ( P = 0.002). Conclusions Amongst a high‐risk cohort, patients undergoing RP performed as predicted by the pre‐treatment surgical nomogram, whereas the patients undergoing HDRB performed significantly better than was predicted by the surgical nomogram at 10 years.